The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Novo Nordisk and Eli Lilly are obvious targets, as both have such treatments already on the market, but clinical-stage players also took it on the chin -- hence the whack absorbed by Structure.

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Political uncertainty in some of the largest European economies has diminished their growth outlook. Read more here.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...